New Long-Term Data Shows Lebrikizumab Sustains Atopic Dermatitis Clearance With Less Frequent Dosing and Advances Findings from Dr. Philip Werschler of Spokane Dermatology Clinic

▤ Summary

Lilly shared long-term trial data showing that lebrikizumab can keep atopic dermatitis under control for up to two years with less frequent dosing. The ADjoin extension study found strong skin-clearance outcomes, reduced itching, and a consistent safety profile across both monthly and biweekly maintenance schedules. Nearly 80% of patients maintained almost clear or clear skin on monthly dosing, which suggests more flexible treatment options for physicians and patients. Dr. Philip Werschler’s role in the earlier Phase 3 research is noted, but the main news centers on the therapy’s sustained clinical performance.

▦ Linked Companies